Modifiedblue cross blue shield - kansasPolicy N/A

Bio-Engineered Skin and Soft Tissue Substitutes

Defines the types, applications, regulatory status, and clinical considerations for bioengineered skin and soft tissue substitutes used for wound healing, burns, and soft-tissue reinforcement; applies to Blue Cross Blue Shield of Kansas members and providers who treat those members.

Policy Summary

Payerblue cross blue shield - kansas

PolicyBio-Engineered Skin and Soft Tissue Substitutes

Policy CodePolicy N/A

Change TypeCoding and product-list revisionsmaterial reclassifications

Effective DateJan 1, 2026

Next Review DateJan 1, 2026

Key ActionVerify member benefits and obtain prior authorization when required; document wound characteristics, prior standard-of-care, and product rationale for requests.

SourceLink

POLICY UPDATE CHANGES

Combined the entries for 'ACell UBM Lyophilized Wound Dressing' and 'ACell UBM Hydrated Wound Dressing' into 'ACell UBM Hydrated / Lyophilized Wound Dressing'.

Moved AlloPatch HD (Q4128) to be medically necessary in Item G.

Removed 'TransCyte**' from Item 3.

Revised Grafix coding entries (Q4132, Q4133) and Amniotic Membrane Grafts asterisk key references in Item G.

Updated the asterisk key used in the coding list.

Added AlloMend to Item A.

Added AlloPatch to Item B and removed Biovance (Q4154), Epifix (Q4131) (Q4145), and Grafix (Q4132) (Q4133) from Item B.

Removed 'TransCyte**' from Item 3.

Revised HCPCS code nomenclature for C9349 (and references to Q4153 effective Jan 1, 2016).

Multiple HCPCS, CPT, and ICD-10 codes were added, removed, or had nomenclature updates across several revisions (examples: added A2002-A2010, A2011-A2013, A2014-A2018, A2019-A2021, A2022-A2025, A2026, A2030-A2034; added CPT codes 15200–15261 and 15011–15018; removed various Q- and C- codes).

The policy's product lists were updated: items were added to both medically necessary lists and experimental/investigational lists (examples: added B6 mVASC® and B7 TheraSkin® to statement B; added numerous products to experimental list).

Clarified that some amniotic membrane/amniotic fluid-related codes were removed and cross-referenced a separate 'Amniotic Membrane and Amniotic Fluid' medical policy.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1products moved to medically necessary

1products removed

1combined product entries

>130products listed as covered or experimental

Feb 21, 2025literature search date

Coverage Criteria and Clinical Rationale

inv-01: General medical necessity considerations

Covered when ALL of the following conditions are met

General clinical necessity: Product selection is for treatment of conditions such as chronic nonhealing wounds, severe burns, or when autografting is not possible or insufficient; objective is to improve healing or provide reinforcement in surgical procedures.

Reflects stated objective and applications

inv-02: Medically necessary uses

Covered when ANY of the following specific indications are met for listed products

Breast reconstruction with ADM: ADM products may be considered medically necessary when: 1) there is insufficient tissue expander or implant coverage by pectoralis major and additional coverage is required; OR 2) there is viable but compromised or thin postmastectomy skin flaps at risk of dehiscence/necrosis; OR 3) reestablishment of undermined inframammary/lateral mammary folds is needed.

Applies to listed ADM products (see policy).

Chronic diabetic full-thickness lower-extremity ulcers: Specific tissue-engineered skin substitutes (AlloPatch, Apligraf, Integra Omnigraft, Integra Flowable, mVASC, TheraSkin) may be considered medically necessary for chronic, noninfected, full-thickness diabetic lower-extremity ulcers.chronic, noninfected, full-thickness

See product list in policy.

Chronic venous insufficiency ulcers: Apligraf and Oasis Wound Matrix may be considered medically necessary for chronic, noninfected, partial- or full-thickness lower-extremity ulcers due to venous insufficiency that have not adequately responded following a 1-month period of conventional ulcer therapy.>1 month of conventional therapy without adequate response

From policy section C.

Dystrophic epidermolysis bullosa: OrCel may be considered medically necessary for treatment of dystrophic epidermolysis bullosa (including HDE-specified use for mitten-hand deformity when standard wound therapy has failed).standard wound therapy failed for mitten-hand deformity per HDE

HDE referenced.

Second- and third-degree burns: Epicel (HDE for deep dermal or full-thickness burns ≥30% TBSA) and Integra Dermal Regeneration Template may be considered medically necessary for treatment of second- and third-degree burns.Epicel: TBSA ≥ 30% and HDE specifications

Policy E.

inv-03: Experimental / Investigational

Not covered / experimental when using products not listed as medically necessary

Experimental/Investigational products: All other uses reviewed herein of the listed bioengineered skin and soft tissue substitutes and all other skin and soft tissue substitutes not specifically named as medically necessary are considered experimental/investigational.

Extensive list of products considered experimental/investigational provided in policy (Item G).

inv-04: Coverage considerations by indication

Clinical evidence summarized; decision-making should weigh benefits and risks for each indication.

Breast reconstruction: RCTs show no consistent difference in overall complication rates between ADM-assisted and standard reconstructions, but ADMs may increase seroma, infection, and necrosis while possibly reducing capsular contracture and implant malposition; product-specific differences and technique (one-stage vs two-stage) influence safety (eg, porcine ADM linked to higher complications in one RCT).

Use when limited tissue coverage necessitates ADM; assess product-specific evidence.

Tendon repair (rotator cuff): One small RCT (GraftJacket) showed improved clinical scores and lower retear rates versus no augmentation, but sample size is limited; additional larger studies needed to confirm benefit.

Consider ADM augmentation in large/multi-tendon tears when supported by clinical judgment and documented rationale.

Hernia/parastomal reinforcement: Current evidence does not support benefit of ADMs over synthetic mesh for hernia repair or parastomal reinforcement; evaluate on a case-by-case basis pending further evidence.

inv-05: Coverage rationale and product-level distinctions

Coverage considerations summarized from the evidence:

Hernia repair/parastomal reinforcement: Current evidence does not demonstrate benefit of acellular dermal matrices (ADMs) over synthetic mesh for hernia repair or prevention of parastomal hernia; additional RCTs are needed to identify any populations who may benefit.evidence negative/mixed

Section summary states lack of support for benefit

Product-level evidence for diabetic foot ulcers: A 2016 Cochrane review pooled 17 trials (N=1655) showing increased likelihood of complete ulcer closure (RR 1.55) and reduced amputations (RR 0.43), but benefits vary by product; Apligraf, EpiFix, and Hyalograft-3D showed benefit while Dermagraft, GraftJacket, Kaloderm, and OrCel did not.product-specific

Policy lists specific products with differential evidence

Comparator and usual care:

inv-06: Coverage criteria aligned to RCT populations

Covered when ALL of the following match clinical trial populations and conditions:

Trial-consistent patient selection

Prior SOC: Documented standard-of-care measures: surgical debridement, adequate off-loading/pressure reduction, appropriate dressings, glucose monitoring
Trials provided SOC to all participants
Failure or inadequate response to conservative therapy: Ulcer not healed with conservative management prior to biologic application
Many trials enrolled chronic non-healing ulcers despite SOC

Products with RCT evidence of efficacy: Use of Apligraf, Dermagraft, AlloPatch, Integra Dermal Regeneration Template (Omnigraft), Integra Flowable Wound Matrix, mVASC, or TheraSkin corresponds to reported RCTs showing improved healing versus SOC

Effect sizes and populations vary by product; see individual trial summaries

inv-07: Evidence-based coverage considerations for bioengineered skin/soft tissue substitutes

Covered when clinical trial-like criteria are met (evidence-based signals from RCTs):

Baseline ulcer characteristics: Chronic diabetic lower-extremity (foot) ulcer of specified minimum duration as in trials (e.g., >=2 to 4 weeks) and documented wound size.see trial-specific enrollment (eg, mean wound size reported in trials)

Trials required minimum ulcer duration (chunks 98,106)

Adequate perfusion: Documentation of adequate vascular perfusion to the affected extremity (as required in PriMatrix and Kerecis trials)clinical documentation of perfusion

Lack of perfusion documentation noted as exclusion in trials (chunks 98,106)

Prior standard of care trial/run-in: Failure to achieve prespecified percent reduction during a run-in SOC period (e.g., <20% or <30% reduction) before application

inv-08: Evidence summaries tied to coverage considerations

Evidence-supported coverage considerations and subgroup findings

Apligraf evidence: RCT evidence demonstrated higher healing rates and shorter median time to closure at 12 weeks to 6 months versus standard care in venous and diabetic ulcer trials; supports coverage when patient matches trial populations.12 weeks to 6 months follow-up

Falanga et al. and other trials summarized in policy

Oasis Wound Matrix evidence: RCTs showed higher healing rates versus SOC at 12 weeks in venous and mixed arteriovenous ulcers and improved time to healing and related outcomes.12 weeks follow-up

Mostow et al. and related studies

Dermagraft evidence: A large RCT in diabetic ulcers showed faster median percent closure and subgroup benefits (eg, ulcer duration ≤12 months or diameter ≤10 cm), but overall ITT primary endpoint results were mixed; venous ulcer use is off-label.

inv-09: Device-specific evidence and implications

Evidence synthesis and device-specific findings relevant to coverage decisions

Epicel (HDE): Epicel is FDA-approved under an HDE for treatment of deep dermal or full-thickness burns comprising TBSA ≥30% and has case-series evidence of survival and permanent coverage comparable to autograft.TBSA >= 30%

HDE status supports use in qualifying patients

Integra Dermal Regeneration Template: Integra has comparative studies and a large postapproval series showing satisfactory take rates and acceptable complication rates; evidence supports use for full-thickness burns and reconstruction when autograft is insufficient.

Heimbach et al. postapproval series and systematic reviews

ReCell Autologous Cell Harvesting Device: ReCell RCTs showed comparable outcomes to standard care and reduced donor skin use in some studies, but heterogeneity and study limitations reduce confidence; additional RCTs needed.

Two RCTs summarized in policy

inv-10: Deep Dermal or Full-Thickness Burns

Coverage conclusions vary by product; include required conditions for products with demonstrated benefit

Epicel (HDE): Epicel is FDA-approved under an HDE for treatment of deep dermal or full-thickness burns comprising a total body surface area of 30% or more; documentation of burn depth and TBSA is required to meet HDE-specified use.TBSA >= 30%

HDE approval implies limited population and documentation requirements

Integra Dermal Regeneration Template: Comparative studies and large series report acceptable take rates and outcomes at least as good as autograft; use is supported for full-thickness burns and reconstruction when autograft is insufficient.

Evidence supports improvement in net health outcome for burns

ReCell has RCTs showing comparable outcomes to standard care but overall evidence limited by heterogeneity; additional RCT evidence in the intended use population is needed before broad coverage expansion.

Use may require additional justification/documentation

inv-11: Diabetic and Venous Lower-Extremity Ulcers

Coverage stance depends on specific product with RCT evidence

Products with RCT-demonstrated benefit: AlloPatch, Apligraf, Dermagraft, Integra, mVASC, and TheraSkin have randomized controlled trials showing efficacy over standard of care for diabetic lower-extremity ulcers; coverage may be considered for these products when patient characteristics align with trial populations.none

Evidence sufficient to determine improvement in net health outcome for these products

Products with insufficient/uncertain evidence: Other ADM or skin substitute products (eg, GraftJacket, DermACELL, Cytal, PriMatrix, Oasis in some comparisons, Omega3 pending larger RCTs) have limited or mixed evidence; these may require additional documentation or be considered investigational for routine coverage.none

May require additional documentation or be considered investigational

inv-12: Pressure Ulcers

RCT evidence mixed; coverage contingent on outcome strength

Oasis Wound Matrix: An RCT of Oasis for stage 3–4 pressure ulcers showed 40% healed at 12 weeks with Oasis + SOC vs 29% with SOC alone (not statistically significant for complete healing); secondary outcomes favored Oasis for near-complete healing but complete healing is the preferred endpoint.none

Longer follow-up or larger studies may be needed to establish benefit

inv-13: Dystrophic Epidermolysis Bullosa (DEB)

Rare disorder with limited evidence; regulatory HDE status noted for OrCel

OrCel was approved under an HDE for use in dystrophic epidermolysis bullosa patients undergoing hand reconstruction to close and heal surgically created wounds; evidence is limited to small series and HDE specifications apply.none

HDE status indicates limited patient population and evidence

inv-14: Use of dermal/skin substitutes (NICE guidance and policy applicability)

Supporting guidance and applicability statements included in this excerpt

NICE recommendation: NICE recommends considering dermal or skin substitutes as an adjunct to standard care for diabetic foot ulcers only when healing has not progressed and on the advice of the multidisciplinary foot care service.

Source: NICE 2023 guidance

Policy dependency: Codes listed are medically necessary ONLY if the procedure is performed according to the 'Policy' section and the member's contract benefits determine coverage.

Operational coverage contingent on full policy criteria and member contract

inv-15: Item G — Revised Product Classifications

Revisions to Item G

Item G classification changes: AlloPatch HD (Q4128) was moved from Item G (experimental/investigational) to a medically necessary listing and ACell UBM Hydrated and Lyophilized entries were combined into 'ACell UBM Hydrated / Lyophilized Wound Dressing'.

Apply these code/name changes when evaluating coverage under Item G

inv-16: Product listing and coding updates

Listing and coding updates: Multiple HCPCS/HCPCS nomenclature and product-list changes were made (examples: AlloPatch HD moved to medically necessary; TransCyte removed from Item 3; HCPCS nomenclature C9349 revised); use updated codes and names when assessing coverage.

These are coding and classification updates that affect item listings and prior authorization processes

inv-16: Product listing and coding updates

Coding and product classification updates: The policy includes numerous additions, removals, and nomenclature revisions to HCPCS/CPT/ICD-10 codes and product listings that should be used when documenting and adjudicating claims; changes are effective on listed dates and impact which products are considered medically necessary versus investigational.

Providers must use current code sets and check member contract benefits

The FDA has not cleared or approved any surgical mesh device for use in breast surgery. The agency considers the use of surgical mesh/ADM in breast reconstruction a new intended use that may require premarket approval rather than 510(k) substantial equivalence review. FDA advisory input and safety communications have noted uncertainty about the safety and effectiveness of ADM use in implant-based breast reconstruction and identified possible higher complication rates with certain ADMs; clinicians and providers should be aware of these regulatory findings when proposing ADM use for breast reconstruction and ensure documentation and justification are available for review.

Per the policy listing, all uses not explicitly identified as medically necessary in the policy are considered experimental/investigational. This means that when a listed bioengineered skin or soft tissue substitute is proposed for an indication that is not included in the policy’s medically necessary sections, the use is treated as investigational and may be denied unless supporting evidence and prior authorization criteria for that specific indication are met.

Any skin or soft tissue substitute that is not specifically named as medically necessary in the policy is considered experimental/investigational for the indications reviewed herein. The policy provides an extensive list of such products (Item G); uses of these products for the reviewed indications should be considered investigational and are not supported for routine coverage absent high-quality comparative evidence.

Procedure, Product, and Billing Codes

FDA product codes referencedmixed

FTM	FDA product code referenced for multiple products (eg, ADMs, living cell therapies)
OXF	FDA product code mentioned in ADM context
KGN	FDA product code referenced for xenogeneic products
FTL	FDA product code referenced for xenogeneic products
QCZ	FDA product code for Recell autologous cell harvesting device
FRO	FDA product code referenced for biosynthetic products
MDD	FDA product code referenced for biosynthetic products
MGR	FDA product code referenced for biosynthetic products
JXI	FDA product code referenced for nerve wraps

Listed product HCPCS/Q/C codesmixed

Q4101	Apligraf
Q4102	Oasis Wound Matrix
Q4103	Oasis Burn Matrix
Q4104	Integra Bilayer Wound Matrix (C9363 listed alongside)
Q4105	Integra Dermal Regeneration Template / Omnigraft
Q4107	GraftJacket
Q4110	PriMatrix
Q4111	GammaGraft
Q4112	Cymetra (Micronized AlloDerm)
Q4113	GraftJacket Xpress, injectable

1–10 of 51

1/6

Procedure and Product Codesmixed

15011	Harvest of skin for autograft; first.
15012	Harvest of skin for autograft; each additional 25 sq cm.
15013	Preparation of skin autograft, requiring enzymatic processing; first 25 sq cm or less.
15014	Preparation of skin autograft, requiring enzymatic processing; each additional 25 sq cm.
15015	Application of skin autograft; first 480 sq cm or less.
15016	Application of skin autograft; each additional 480 sq cm.
15017	Application of skin autograft; first 480 sq cm or less.
15018	Application of skin autograft; each additional 480 sq cm.
15040	Harvest of skin for tissue cultured skin autograft, 100 sq cm or less.
15050	Pinch graft, single or multiple, up to defect size 2 cm diameter.

1–10 of 54

1/6

Listed A-codes and A6460HCPCS

A2012	Suprathel, per square centimeter
A2013	Innovamatrix fs, per square centimeter
A2014	Omeza collagen matrix, per 100 mg
A2015	Phoenix wound matrix, per square centimeter
A2016	Permeaderm B, per square centimeter
A2017	Permeaderm Glove, each
A2018	Permeaderm c, per square centimeter
A2019	Kerecis omega3 marigen shield, per square centimeter
A2020	Ac5 advanced wound system (ac5)
A2021	Neomatrix, per square centimeter

1–10 of 28

1/3

Selected C- and Q-codes (partial list)HCPCS

A6461	Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing
C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm
C9356	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm
C9358	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
C9360	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per square cm
C9364	Porcine implant, Permacol, per sq cm
Q4101	Apligraf, per sq cm
Q4102	Oasis wound matrix, per sq cm
Q4103	Oasis burn matrix, per sq cm

1–10 of 40

1/4

Additional Q-codesHCPCS

Q4149	Excellagen, 0.1 cc
Q4152	Dermapure, per sq cm
Q4158	Kerecis Omega3, per sq cm
Q4161	Bio-ConneKt wound matrix, per sq cm
Q4164	Helicoll, per sq cm
Q4165	Keramatrix or Kerasorb, per sq cm
Q4166	Cytal, per sq cm
Q4167	Truskin, per sq cm
Q4175	Miroderm, per sq cm
Q4179	FlowerDerm, per sq cm

1–10 of 20

1/2

Revised E/I skin and soft tissue substitute HCPCS/Q-codesHCPCSCovered

Q4128	AlloPatch HD
Q4132	Grafix
Q4133	Grafix
Q4145	ACell UBM Hydrated / Lyophilized Wound Dressing

Removed entriesmixedNot Covered

TransCyte (removed from Item 3)

Medically necessary product (moved)HCPCSCovered

Q4128

AlloPatch HD

Revised HCPCS NomenclatureHCPCS

C9349	Revised HCPCS code nomenclature referenced in policy
Q4153	HCPCS code referenced (effective Jan 1, 2016)

Removed from Item BHCPCSNot Covered

Q4154	Biovance (removed from Item B)
Q4131	Epifix (removed from Item B)
Q4132	Grafix (removed from Item B)
Q4133	Grafix (alternate) (removed from Item B)

Combined product listingmixed

ACell UBM (hydrated/lyophilized)

ACell UBM Hydrated / Lyophilized Wound Dressing (combined listing)

Added CPT CodesCPT

15011	Added CPT (eff. 01-01-2025)
15012	Added CPT (eff. 01-01-2025)
15013	Added CPT (eff. 01-01-2025)
15014	Added CPT (eff. 01-01-2025)
15015	Added CPT (eff. 01-01-2025)
15016	Added CPT (eff. 01-01-2025)
15017	Added CPT (eff. 01-01-2025)
15018	Added CPT (eff. 01-01-2025)
15200	Added CPT code (autograft/skin substitute related)
15201	Added CPT code

1–10 of 16

1/2

Added/Updated HCPCS CodesHCPCS

A2002	Added HCPCS (eff. 01-01-2022)
A2003	Added HCPCS (eff. 01-01-2022)
A2004	Added/updated nomenclature
A2005	Added HCPCS
A2006	Added HCPCS
A2007	Added HCPCS
A2008	Added HCPCS
A2009	Added HCPCS
A2010	Added HCPCS
A2011	Added HCPCS (new codes 04-01-2022)

1–10 of 30

1/3

Added ICD-10 Codes / rangesICD-10

L89.016	Added ICD-10 (example of many added)
E08.621-E08.622	Added ICD-10 range
T34.011-T34.99	Added ICD-10 range

ModifiersModifier

-JC	HCPCS modifier: skin substitute used as a graft
-JD	HCPCS modifier: skin substitute not used as a graft

Removed HCPCS CodesHCPCS

Q4177	Removed HCPCS (placed in amniotic membrane policy)
Q4178	Removed HCPCS (placed in amniotic membrane policy)
Q4181	Removed HCPCS (placed in amniotic membrane policy)

Burn size threshold for Epicel HDEmixed

Epicel HDE TBSA threshold

Total body surface area ≥ 30%

Run-in wound area reduction threshold — trial screening

Run-in wound area reduction exclusion used in trials20% (used in some Kerecis trial run-in definitions) or 30% (used in PriMatrix run-in to exclude wounds with >=30% area reduction)

Purpose of run-in periodTo exclude wounds that reduce substantially in area with standard-of-care before randomization

Implication for authorizationDocument percent area reduction during any SOC run-in to determine eligibility consistent with trial criteria

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Verify benefits and consider prior review

Verify member benefits and prior authorization requirements with Blue Cross and Blue Shield of Kansas Customer Service before procurement or placement. Coverage determinations are contingent on the member's contract and applicable state and federal mandates; the policy lists medically necessary products and those considered experimental/investigational and updates to those listings may change prior authorization implications.

Coverage contingent on policy and member contract — confirm benefits prior to service.
Prior authorization implications for revised product listings — products moved between medically necessary and experimental/investigational (for example AlloPatch HD Q4128) may change authorization requirements.
Verify prior authorization for newly added or removed HCPCS/CPT codes before billing.

Prior Authorization

Prior authorization may be required

Prior authorization may be required per plan rules for certain listed products, HCPCS/Q-codes, and procedures. Providers should confirm whether plan-specific prior authorization applies for xenogeneic ADMs, one-stage implant-based breast reconstruction, and newly coded or reclassified products.

Background and Scope

Bioengineered skin and soft tissue substitutes include acellular and cellular products derived from human allograft tissue, xenogeneic animal sources (eg, porcine or fish skin), synthetic or biosynthetic scaffolds, and composite or living-cell therapies. Acellular dermal matrices (ADMs) are biologic scaffolds composed mainly of extracellular matrix (eg, collagen) with cellular components removed; cellular products and living-cell therapies contain viable cells such as keratinocytes or fibroblasts within a matrix (examples include bilayered living skin constructs). These products are used as temporary or permanent wound coverings, to promote healing in chronic nonhealing wounds (diabetic, venous, pressure), to treat burns, and to provide soft-tissue reinforcement in reconstructive procedures. Regulatory status varies by product—some are regulated as banked human tissue, others have 510(k) clearance, PMA, or HDE designations—so clinical use and coverage determinations should reference both the product’s regulatory classification and the policy’s specified medically necessary indications.

Definitions and Product Descriptions

Acellular dermal matrix (ADM)

DefinitionA dermal scaffold derived from tissue with cellular components removed, composed of matrix materials such as collagen, used as a graft or scaffold

Sources and processingMay be derived from human, bovine, or porcine sources and processed to remove cells; human ADMs may be regulated as banked human tissue

Clinical useUsed to support soft-tissue reconstruction, wound healing, or reinforcement in surgical procedures

Cellular products / living cell therapy

DefinitionProducts that contain living cells (eg, fibroblasts, keratinocytes) within a matrix or bilayer construct

ExamplesApligraf (bilayered living cell therapy); Epicel (cultured epithelial autograft) is a living-cell-based product for burns

Revision Notes and References

Accessed March 23-25, 2025bibliography_updated

References section lists FDA guidance and AHRQ/technology assessment sources relevant to regulatory and evidence context for skin and soft tissue substitutes.

03-20-2017hcpcs_nomenclature_revision

Revised HCPCS code nomenclature (C9349) and updated cross-reference to amniotic membrane policy.

2023-03-30coding_updates_effective

Policy Summary

Payerblue cross blue shield - kansas

PolicyBio-Engineered Skin and Soft Tissue Substitutes

Policy CodePolicy N/A

Change TypeCoding and product-list revisionsmaterial reclassifications

Effective DateJan 1, 2026

Next Review DateJan 1, 2026

Key ActionVerify member benefits and obtain prior authorization when required; document wound characteristics, prior standard-of-care, and product rationale for requests.

SourceLink

On This Page

Compare to synthetic mesh alternatives; document rationale.

Standard wound care (regular debridement and moist wound covering) is the usual comparator and should be considered prior to use of skin substitutes except where clinical circumstances dictate earlier use.

standard care attempted

Comparator defined in document

run-in reduction thresholds used in trials

Multiple RCTs used run-in periods to exclude rapidly healing wounds (chunks 98,106,107)

Product-specific evidence of benefit: RCT evidence demonstrating a statistically significant higher proportion of complete healing at trial endpoints for the product versus SOC (examples: DermACELL at 16 weeks, PriMatrix at 12 weeks, Kerecis Omega3 at 12 weeks)trial-specific endpoints (commonly 12 weeks)

See chunks 94,99,107 for trial results

subgroup criteria (≤12 months duration or ≤10 cm diameter)

Harding et al. and subsequent analyses

DermACELL evidence: A small substudy in venous ulcers (n=18) did not show benefit over SOC; evidence insufficient to support routine coverage for venous ulcers.small sample size

Cazzell 2019 substudy

Kerecis/Omega3 evidence limitations: Kerecis Omega3 trials show positive findings in a published RCT but have unpublished completed trials and notable limitations (incomplete follow-up, study heterogeneity) that warrant cautious interpretation.evidence limitations noted

Lantis et al. and trial registry entries

Omega3 Wound (acellular fish skin graft): Evidence for Omega3 Wound is limited to preclinical studies, case series, and a small cohort; RCT evidence is limited but a recent RCT reported benefit at 12 weeks—larger published RCTs and complete reporting needed.

Systematic review and recent trial publications referenced

Dystrophic Epidermolysis Bullosa: OrCel had HDE approval for hand reconstruction in dystrophic epidermolysis bullosa, but evidence consists of small series and is insufficient to determine net health outcome.

HDE status and limited evidence

Primary trial endpoint timing

Common primary endpoint timing in RCTs12 weeks (typical assessment point for incidence of complete wound closure)

Other typical timepointsAdditional assessments at 6 months and up to 1 year for longer-term outcomes

Regulatory alignmentTimepoints consistent with FDA guidance for chronic cutaneous ulcer and burn wound trials

Epicel HDE TBSA threshold

Epicel HDE burn-size threshold>= 30% total body surface area (TBSA)

Indication contextApproved under an HDE for deep dermal or full-thickness burns meeting the TBSA threshold

Documentation implicationPrior authorization should document burn depth and percent TBSA when Epicel is requested

Wound surface area coding thresholds

CPT graft/harvest unit thresholdsCodes reference units such as 25 sq cm, 100 sq cm, 480 sq cm, and 20 sq cm for harvest/application descriptors

Examples - autograft/skin substitute application15013/15014/15015/15016 (25 sq cm increments), 15150–15152 (25–100+ sq cm cultured autograft), 15271–15278 (skin substitute application by 25/100/480 sq cm thresholds)

Full-thickness graft coding15260/15261 describe full-thickness grafts with 20 sq cm and additional 20 sq cm units

Not applicable

ApplicabilityNot applicable

NotesNo threshold value provided in this item

Prior authorization recommended for xenogeneic ADMs (eg, porcine Strattice) and for one-stage IBBR due to safety signal.
Prior authorization may require clinical justification when product listings have changed status.
Verify requirements for new HCPCS codes (A-codes added 2022–2024, revisions effective dates listed in coding section).

Documentation Required

Prior authorization: clinical eligibility documentation

Document clinical eligibility and required clinical information when requesting prior authorization. Requests should include indication-specific details, prior standard-of-care (SOC) treatments and responses, perfusion status where applicable, and product, indication, and rationale to support medical necessity.

Required clinical documentation: diagnosis, wound duration, size, Wagner grade (for diabetic foot ulcers), prior SOC therapies and duration, prior debridement and off-loading, prior compression for venous ulcers.
Documentation of adequate vascular perfusion/perfusion testing for lower-extremity wounds when required by trial eligibility.
Run-in SOC response: patients with substantial improvement (eg, ≥30% wound reduction during SOC run-in) were often excluded from trials and may be poor candidates — include run-in data.
For burn indications, include TBSA, burn depth (deep dermal or full-thickness), and HDE compliance documentation (Epicel).
Providers must submit product name and HCPCS/CPT code used, clinical indication, number of applications, and expected clinical outcome measures.

Step Therapy

Prior authorization to confirm SOC attempted

Standard wound care should generally be attempted first and documented before considering bioengineered products. Prior authorization reviews will expect evidence that conventional therapies were used and that healing did not progress with SOC, consistent with RCT run-in designs and guidance (eg, NICE).

Require prior SOC trial (debridement, moist dressings, off-loading for diabetic foot ulcers) and duration consistent with trials (commonly a 2–4 week run-in).
For venous leg ulcers, prior compression therapy must be documented.
Stepwise therapy: consider skin substitutes only after inadequate response to standard therapy; no universal step therapy mandate is specified in the policy but documentation of SOC trial is expected.

Denial Risk

Experimental / Investigational exclusions

Some product indications and device classifications were moved between medically necessary and experimental/investigational in recent updates. Uses not listed as medically necessary in the Policy section remain experimental/investigational and are not covered. Providers should not assume coverage for products listed in the experimental/investigational section.

All uses not explicitly listed as medically necessary (Policy A–E) are considered experimental/investigational.
ReCell was added to the experimental/investigational list in a 2023 update for certain indications; ReCell evidence limitations are noted.
ADM products and other items listed in Section G are E/I unless specifically moved to medically necessary in the Policy updates.

Denial Risk

Safety signals and evidence insufficiency that may trigger review

Evidence limitations and safety signals may affect coverage decisions. Porcine ADM (Strattice) was associated with higher complications and led to early trial termination in a randomized trial; this safety signal may prompt additional review or prior authorization justification. Evidence for use of ADMs in hernia repair is insufficient to demonstrate superiority to synthetic mesh.

Safety signal: porcine ADM (Strattice) in one-stage IBBR showed higher surgical complications and reoperation in an RCT — may require justification for xenogeneic ADM use.
Evidence insufficiency for hernia repair: current evidence does not support benefit of ADMs vs synthetic mesh and may trigger additional review.
Evidence exclusion may affect coverage — limited or poor-quality data, unpublished trials, or trial heterogeneity can lead to denial or additional documentation requests.

Note

Evidence limitations and level expectations

Trials and systematic reviews often had limitations (heterogeneous populations, incomplete reporting, industry sponsorship, unpublished completed trials). Such evidence limitations may prompt requests for additional clinical information during prior authorization and may affect coverage determinations.

Evidence limitations that may trigger additional review: incomplete data, unpublished trials listed on ClinicalTrials.gov, asymmetric publication bias, and trial heterogeneity.
Evidence-level expectations: preference for RCTs and comparative prospective studies; single-arm studies may be used for long-term outcomes but are lower-level evidence.
ReCell evidence: two RCTs exist but heterogeneity and study limitations reduce confidence; additional RCT evidence in target populations is needed.

Billing Rule

Use specified HCPCS/CPT codes and updated coding guidance

Coding and billing must reflect current HCPCS/CPT nomenclature and the policy's coding updates. Providers must use the updated code names and assignments when submitting claims; removed codes should not be billed. Misassignment or use of removed codes risks claim denial or recoupment.

Providers must submit claims using the listed HCPCS/CPT codes that correspond to the covered product and indication; check effective dates for newly added A-codes and Q-codes.
Coding name updates: use updated nomenclature (eg, Q4128 nomenclature revisions, C9349 revisions) when documenting.
Removed coding: several HCPCS codes (eg, Q4260, Q4261, 0717T, 0718T; earlier removals listed) were removed — verify current code list before billing.
Code assignment risks: product reclassification (E/I -> medically necessary or vice versa) can change allowable coding and prior authorization requirements.

Regulatory noteRegulatory status varies by product (PMA, HDE, 510(k), or regulated as HCT/P) and affects coverage considerations

Autologous cell harvesting device (ReCell)

Device descriptionA device that prepares an autologous regenerative epidermal suspension at the point of care (ReCell)

IndicationsApproved under PMA for use with meshed autografting for acute partial- and full-thickness burns and certain skin defects

Regulatory codeFDA product code: QCZ

ADM in breast reconstruction

Use in breast reconstructionBiologic scaffold used to provide additional support or tissue coverage in implant-based breast reconstruction

Regulatory status noteFDA has not cleared or approved any surgical mesh device specifically for use in breast surgery; ADM use in breast reconstruction is considered nonhomologous by FDA

Safety concernsPorcine ADM (eg, Strattice) was associated with higher complications in a 1-stage IBBR trial and may require additional justification

Synthetic products / Nerve wraps

DefinitionSynthetic copolymer membranes used for temporary coverage of superficial burns and wounds (eg, Suprathel)

Nerve wrap examplesAxoGuard and various collagen-based nerve cuffs/wraps are synthetic/processed devices used to protect peripheral nerves and reduce scarring

Typical applicationUsed for temporary wound coverage or to provide a barrier around repaired peripheral nerves to limit adhesions

ADM (acellular dermal matrix)

DefinitionA biologic soft-tissue substitute derived from human or animal dermis processed to remove cells

PurposeUsed to support soft-tissue reconstruction, augmentation, or reinforcement in surgical repairs

VariabilityProducts vary by species source, processing, hydration state, and additives which can affect clinical performance

Bioengineered soft tissue substitute

DefinitionEngineered allogeneic or xenogeneic matrices and scaffolds intended to replace or augment native soft tissue

ApplicationsUsed for wound healing, soft tissue reinforcement (eg, tendon, hernia), and as adjuncts to autografting

Regulatory variabilityMay be regulated as HCT/Ps, 510(k) devices, PMA, or other pathways depending on processing and intended use

Bioengineered matrix support / skin substitute

DefinitionBiologic materials used to support soft tissue repair or to promote wound healing (eg, acellular dermal matrices, engineered skin products)

Role in careIntended as adjuncts to standard wound care to improve closure rates or provide structural support

Evidence considerationProduct-level RCT evidence varies and should guide coverage decisions

Primary endpoints for wound trials

Primary endpointsIncidence of complete wound closure, time to complete wound closure, incidence after surgical closure, and pain control

Typical assessment timepointsCommonly assessed at 12 weeks, 6 months, with longer-term outcomes up to 1 year

Regulatory alignmentEndpoints consistent with FDA guidance for chronic cutaneous ulcer and burn wound trials

Standard of Care (SOC)

Standard componentsSurgical debridement, off-loading/pressure reduction, and appropriate moist dressings (and compression where indicated)

Role in trialsSOC was provided to all participants in RCTs and is the usual comparator to skin substitutes

Authorization implicationDocumentation that SOC was attempted should be provided for coverage determinations where trial-like criteria are required

Complete wound healing / closure

Definition in trials100% re-epithelialization with no drainage; often confirmed by blinded adjudication or planimetry

Common assessmentTypically assessed at 12 weeks in many RCTs as the primary endpoint

Clinical relevanceComplete closure is the preferred primary outcome for demonstrating product efficacy

Complete wound closure (trial definition)

Trial definition100% re-epithelialization without drainage and no need for dressing, typically assessed at 12 weeks

MeasurementAssessed by investigators and often confirmed by blinded adjudication or computerized planimetry

Endpoint useUsed as primary endpoint in multiple RCTs cited in the policy

Run-in period

DefinitionA pre-randomization SOC treatment period used in trials to exclude wounds that reduce substantially in area (eg, >=20% or >=30%) before enrollment

Trial examplesPriMatrix used a 2-week run-in excluding wounds with >=30% reduction; Kerecis-related trials used a 20% run-in threshold in some designs

Implication for coverageDocumentation of run-in response (percent area reduction) may affect eligibility for product coverage

Primary wound closure endpoints

Primary endpointsIncidence of complete wound closure and time to complete wound closure, consistent with FDA guidance

Typical follow-upMeasured at 12 weeks, with additional follow-up at 6 months and up to 1 year for longer-term outcomes

Regulatory noteEndpoints align with FDA recommendations for chronic ulcers and burn wound trials

Standard of care (SOC) for venous ulcers

SOC for venous ulcersDebridement of necrotic tissue plus compression therapy (multicomponent compression systems preferred)

EvidenceCochrane and RCT evidence support compression as effective comparators with typical healing assessed at ~12 weeks

Authorization implicationDocument trial of adequate compression prior to advanced substitutes for venous ulcers

Complete wound closure (outcomes)

DefinitionIncidence of full re-epithelialization used in trials and FDA guidance; common timepoints include 4, 8, 12 weeks, 6 months, and up to 1 year

Outcome measuresIncludes complete closure rates, time to closure, pain, and need for amputation or surgical closure

DocumentationOutcomes should be recorded to support medical necessity and follow-up assessments

HDE (Humanitarian Device Exemption)

HDE definitionA regulatory pathway (Humanitarian Device Exemption) allowing FDA approval for devices intended to treat conditions affecting small populations

Products with HDEsEpicel and OrCel have had HDE approvals for specified severe-burn or rare-disease indications

Coverage implicationHDE status requires documentation of indication and applicability to the limited intended population

HDE (Humanitarian Device Exemption) — definition

HDE pathwayFDA pathway for devices intended to treat conditions affecting fewer than a threshold number of patients; approvals are for limited populations

Clinical implicationUse outside the HDE-specified population may not be supported by evidence or coverage

DocumentationRequests for HDE products should include supporting documentation of disease severity and TBSA where applicable

Dermal or skin substitutes

DefinitionBioengineered or biologic products used as adjuncts to standard wound care to promote healing (eg, diabetic foot ulcers, venous ulcers, burns)

Clinical roleIntended to augment SOC when wounds are nonhealing or autografting is insufficient

Evidence variabilityProduct-level RCT evidence varies widely and should guide use and coverage

HCPCS/CPT entries

DefinitionProduct-specific billing codes with unit descriptors (eg, per square centimeter, per mg, per cc) used to report bioengineered skin and soft tissue substitutes

Coding implicationClaims must use the appropriate HCPCS/CPT/Q/C code and unit descriptor corresponding to the product and quantity applied

DocumentationProviders should document product name, units applied, and corresponding code for accurate billing

ACell UBM Hydrated / Lyophilized Wound Dressing

ACell UBM combined listingACell UBM Hydrated and Lyophilized Wound Dressing entries combined into 'ACell UBM Hydrated / Lyophilized Wound Dressing'

Policy effectApply the combined product name/nomenclature when documenting and billing

Revision sourceItem G coding revisions reflected in the policy updates

AlloPatch HD (Q4128)

AlloPatch HD statusAlloPatch HD (Q4128) was moved from experimental/investigational to medically necessary in Item G

Coding noteUse HCPCS code Q4128 (AlloPatch HD) per updated Item G listings when requesting authorization or billing

ImplicationProduct reclassification may alter prior authorization and coverage determinations

ACell UBM Hydrated / Lyophilized Wound Dressing

Combined listingACell UBM Hydrated / Lyophilized Wound Dressing denotes the merged entries for previously separate hydrated and lyophilized products

DocumentationProviders should use the combined product name and corresponding HCPCS/Q-code when submitting claims

Revision rationaleAdministrative coding revision recorded in Item G updates

Skin substitute — scope and definition

DefinitionNo single standard definition exists; the review covers products that may not require FDA approval/clearance and products cleared via 510(k)

ScopeIncludes acellular, cellular, xenogeneic, biosynthetic, synthetic, and living-cell therapies used as temporary or permanent wound coverings

Regulatory noteFDA product codes and regulatory pathways vary across products and affect coverage and documentation requirements

Regulatory guidance sources

Regulatory and guidance sourcesPolicy cites FDA guidance on HCT/Ps and ADM safety communications, CMS fact sheets, and NICE guidance among references

Evidence sourcesSystematic reviews, RCTs, registries, and regulatory documents are referenced to inform coverage rationale

Provider actionRefer to cited guidance and regulatory communications when preparing prior authorization documentation

Multiple HCPCS codes and nomenclature updates posted (examples include additions to A‑code series and updates to Q4128 nomenclature).

2026-01-01policy_effective_dateLatest

Document effective date and last review set to 2026-01-01 with multiple incremental coding and product-list revisions through 2026-01-01 recorded in the policy brief.

The policy includes numerous coding updates over several revisions with effective dates through 01-01-2026. Multiple HCPCS, CPT, and ICD-10 codes were added, removed, or had nomenclature updates; new CPT codes related to autograft/skin substitute harvest and application (for example, the 15011–15018 and 15200–15261/15271–15278 ranges) and many A- and Q-codes were added or revised. Providers must use the current code sets shown in the coding section and should verify applicable prior authorization requirements and billing codes for the date of service to avoid claim denials.